Zacks Investment Research upgraded shares of Xencor (NASDAQ:XNCR) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “
A number of other research analysts also recently weighed in on the company. Canaccord Genuity set a $36.00 target price on Xencor and gave the stock a buy rating in a report on Monday, October 23rd. Cantor Fitzgerald started coverage on Xencor in a report on Wednesday, November 29th. They set an overweight rating and a $33.00 target price on the stock. Piper Jaffray Companies reissued a buy rating and issued a $35.00 price target on shares of Xencor in a research report on Sunday, November 12th. BidaskClub raised Xencor from a strong sell rating to a sell rating in a research report on Thursday, December 7th. Finally, ValuEngine cut Xencor from a hold rating to a sell rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $30.80.
Xencor (NASDAQ XNCR) opened at $24.40 on Tuesday. Xencor has a twelve month low of $18.55 and a twelve month high of $28.64. The firm has a market capitalization of $1,150.00, a P/E ratio of -24.16 and a beta of 1.97.
In related news, major shareholder John S. Stafford III purchased 5,349 shares of the company’s stock in a transaction dated Friday, November 24th. The shares were purchased at an average cost of $19.85 per share, with a total value of $106,177.65. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul A. Foster sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.01, for a total value of $125,050.00. Following the completion of the sale, the insider now directly owns 7,419 shares in the company, valued at $185,549.19. The disclosure for this sale can be found here. Over the last three months, insiders bought 36,153 shares of company stock worth $731,583. Insiders own 4.14% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Xencor by 2.3% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock worth $492,000 after purchasing an additional 521 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Xencor by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,771 shares of the biopharmaceutical company’s stock valued at $629,000 after acquiring an additional 1,673 shares in the last quarter. Nationwide Fund Advisors lifted its position in Xencor by 4.5% in the 3rd quarter. Nationwide Fund Advisors now owns 62,180 shares of the biopharmaceutical company’s stock valued at $1,425,000 after acquiring an additional 2,676 shares in the last quarter. Vident Investment Advisory LLC lifted its position in Xencor by 5.9% in the 4th quarter. Vident Investment Advisory LLC now owns 59,426 shares of the biopharmaceutical company’s stock valued at $1,303,000 after acquiring an additional 3,289 shares in the last quarter. Finally, Swiss National Bank lifted its position in Xencor by 5.2% in the 3rd quarter. Swiss National Bank now owns 66,400 shares of the biopharmaceutical company’s stock valued at $1,522,000 after acquiring an additional 3,300 shares in the last quarter. 77.11% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/21/xencor-xncr-upgraded-to-hold-at-zacks-investment-research.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.